Roquefort Therapeutics plc (LON:ROQ)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1.700
-0.100 (-5.56%)
Jun 13, 2025, 4:35 PM BST
-65.31%
Market Cap 2.79M
Revenue (ttm) n/a
Net Income (ttm) -971.80K
Shares Out 154.98M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,399,067
Average Volume 1,199,176
Open 1.660
Previous Close 1.800
Day's Range 1.600 - 2.000
52-Week Range 1.320 - 6.780
Beta -0.31
RSI 42.24
Earnings Date Jun 27, 2025

About Roquefort Therapeutics

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in v... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 7
Stock Exchange London Stock Exchange
Ticker Symbol ROQ
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.